India is all set to launch on Thursday its first indigenously developed quadrivalent Human Papilloma Virus (HPV) vaccine for prevention of cervical cancer. It has been developed by the Serum Institute of India in partnership with the Department of Biotechnology. Till now, HPV vaccines needed to prevent cervical cancer have been sourced from foreign manufacturers at a cost of Rs 2,000 to Rs 3,500 per dose.